Cardiovascular safety and effectiveness of vildagliptin in patients with type 2 diabetes mellitus: a 3-year, large-scale post-marketing surveillance in Japan

References

• Fox C, Coady S, Sorlie P, et al. The Framingham Heart Study. Increasing cardiovascular disease burden to diabetes mellitus. Circulation. 2007;115:1544–1550.
   PubMed Web of Science ®Google Scholar
• Gerstein H, Capes S. Dysglycemia: a key cardiovascular risk factor. Semin Vasc Med. 2002;2:165–174.
   PubMedGoogle Scholar
• Martín-Timón I, Sevillano-Collantes C, Segura-Galindo A, et al. Type 2 diabetes and cardiovascular disease: have all risk factors the same strength? World J Diabetes. 2014;5:444–470.
   PubMedGoogle Scholar
• Ahren B, Landin-Olsson M, Jansson P, et al. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab. 2004;89:2078–2084.
   PubMed Web of Science ®Google Scholar
• Utzschneider K, Tong J, Montgomery B, et al. The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose. Diabetes Care. 2008;31:108–113.
   PubMed Web of Science ®Google Scholar
• Halimi S, Schweizer A, Minic B, et al. Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet. Vasc Health Risk Manag. 2008;4:481–492.
   PubMedGoogle Scholar
• Bosi E, Camisasca R, Collober C, et al. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care. 2007;30:890–895.
   PubMed Web of Science ®Google Scholar
• Garber A, Schweize A, Baron M, et al. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab. 2007;9:166–174.
   PubMed Web of Science ®Google Scholar
• Garber A, Foley J, Banerji M, et al. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obes Metab. 2008;10:1047–1056.
   PubMed Web of Science ®Google Scholar
• Fonseca V, Baron M, Shao Q, et al. Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus. Horm Metab Res. 2008;40:427–430.
   PubMed Web of Science ®Google Scholar
• Kikuchi M, Abe N, Kato M, et al. Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2009;83:233–240.
   PubMed Web of Science ®Google Scholar
• Nissen S, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457–2471.
   PubMed Web of Science ®Google Scholar
• Udell J, Cavender M, Bhatt D, et al. Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 2015;3:356–366.
   PubMed Web of Science ®Google Scholar
• Scirica B, Bhatt D, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317–1326.
   PubMed Web of Science ®Google Scholar
• White W, Cannon C, Heller S, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327–1335.
   PubMed Web of Science ®Google Scholar
• Green J, Bethel M, Armstrong P, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373:232–242.
   PubMed Web of Science ®Google Scholar
• McInnes G, Evans M, Del Prato S, et al. Cardiovascular and heart failure safety profile of vildagliptin: a meta-analysis of 17 000 patients. Diabetes Obes Metab. 2015;17:1085–1092.
   PubMed Web of Science ®Google Scholar
• Murayama H, Toda M, Tsumiyama I, et al. Relationship of patient background with macro- and microvascular complications: a 2-year post-marketing surveillance of vildagliptin in nearly 20,000 Japanese diabetic patients. Expert Opin Pharmacother. 2019;20:1037–1047.
   PubMed Web of Science ®Google Scholar
• Hayashi T, Murayama H, Shinfuku Y, et al. Safety and efficacy of vildagliptin: 52-week post-marketing surveillance of Japanese patients with type 2 diabetes in combination with other oral antidiabetics and insulin. Expert Opin Pharmacother. 2019;5:1–10.
   Google Scholar
• Ueshima H, Sekikawa A, Miura K, et al. Cardiovascular disease and risk factors in Asia: A selected review. Circulation. 2008;118:2702–2709.
   PubMed Web of Science ®Google Scholar
• Japan Diabetes Clinical Data Management Study Group [Internet]. C2009–2018. Japan Diabetes Clinical Data Management Study Group. [ cited 2018 Jul 23]. Available from: http://jddm.jp/data/index-2016.html
   Google Scholar
• Snell-Bergeon JK, Wadwa RP. Hypoglycemia, Diabetes, and Cardiovascular Disease. Diabetes Technol Ther. 2012;14(Suppl1):S-51–S-58.
   Google Scholar
• Hanefeld M. Hypoglycemia and cardiovascular risk: is there a major link? Diabetes Care. 2016;39(Suppl 2):S205–S209.
   PubMed Web of Science ®Google Scholar
• Farngren J, Persson M, Schweizer A, et al. Glucagon dynamics during hypoglycaemia and food-re-challenge following treatment with vildagliptin in insulin-treated patients with type 2 diabetes. Diabetes Obes Metab. 2014;16:812–818.
   PubMed Web of Science ®Google Scholar
• Sakamoto M, Nishimura R, Irako T, et al. Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J-VICTORIA study). Cardiovasc Diabetol. 2012;11:92.
   PubMed Web of Science ®Google Scholar
• Guerci B, Monnier L, Serusclat P, et al. Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study. Diabetes Metab. 2012;38:359–366.
   PubMed Web of Science ®Google Scholar
• Rizzo M, Barbieri M, Marfella R, et al. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care. 2012;35:2076–2082.
   PubMed Web of Science ®Google Scholar
• Sone H, Tanaka S, Tanaka S, et al. Serum level of triglycerides is a potent risk factor comparable to LDL cholesterol for coronary heart disease in Japanese patients with type 2 diabetes: subanalysis of the Japan Diabetes Complications Study (JDCS). J Clin Endocrinol Metab. 2011;96:3448–3456.
   PubMed Web of Science ®Google Scholar
• Yokoyama H, Matsushima M, Kawai K, et al. Low incidence of cardiovascular events in Japanese patients with Type 2 diabetes in primary care settings: a prospective cohort study (JDDM 20). Diabet Med. 2011;28:1221–1228.
   PubMed Web of Science ®Google Scholar
• Schweizer A, Dejager S, Foley JE, et al. Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population. Diabetes Obes Metab. 2010;12:485–494.
   PubMed Web of Science ®Google Scholar
• Kadowaki T, Haneda M, Ito H, et al. Long-term, real-world safety and efficacy of teneligliptin: a post-marketing surveillance of more than 10,000 patients with type 2 diabetes in Japan. Adv Ther. 2019 Dec 23. DOI:10.1007/s12325-019-01189-w
   PubMed Web of Science ®Google Scholar
• Yamamoto F, Unno Y, Okamura T, et al. Long-term safety and effectiveness of linagliptin in Japanese patients with type 2 diabetes mellitus: a 3-year post-marketing surveillance study. Diabetes Ther. 2019 Nov 11. DOI:10.1007/s13300-019-00723-x
   Web of Science ®Google Scholar
• Kim YG, Hahn S, Oh TJ, et al. Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis. Diabetologia. 2013;56:696–708.
   PubMed Web of Science ®Google Scholar
• Davis TME, Mulder H, Lokhnygina Y, et al. Effect of race on the glycaemic response to sitagliptin: insights from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). Diabetes Obes Metab. 2018;20:1427–1434.
   PubMed Web of Science ®Google Scholar
• Pi-Sunyer F, Schweizer A, Mills D, et al. Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes. Diab Res Clin Pract. 2007;76:132–138.
   PubMed Web of Science ®Google Scholar
• Dejager S, Razac S, Foley J, et al. Vildagliptin in drug-naive patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res. 2007;39:218–223.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Baron M, Dejager S, et al. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diab Care. 2007;30:217–223.
   PubMed Web of Science ®Google Scholar
• Fonseca V, Schweizer A, Albrecht D, et al. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia. 2007;50:1148–1155.
   PubMed Web of Science ®Google Scholar